Meningioma verification in the clinic depends primarily on HE histology and perhaps the immunohistochemical markers vimentin, epithelial membrane antigen (EMA), somatostatin receptor 2 (SSTR2), and Ki67/MIB-1. This evidence concerns the gene MIB1 and meningioma.